MicroTransponder
Series F in 2025
MicroTransponder is a medical device company that develops and commercializes implantable neurostimulation platforms aimed at treating neurological conditions. The company focuses on vagus nerve stimulation to promote neuroplasticity and functional recovery, with products including the Serenity System for tinnitus and Vivistim, an FDA-approved therapy for ischemic stroke survivors with moderate to severe upper-limb impairment more than six months post-stroke. Founded in 2007 and headquartered in Austin, Texas, MicroTransponder's technology combines paired vagus nerve stimulation with wireless delivery of targeted electrical impulses to enhance recovery after neurological injury and disease.
Shoulder Innovations
Series E in 2025
Shoulder Innovations designs and manufactures medical devices for shoulder replacement surgery, focusing on inset glenoid fixation technology to provide a stable glenoid platform and reliable fixation. Its product portfolio includes InSet Total Shoulder Arthroplasty, InSet Reverse Shoulder Arthroplasty, ProVoyance Shoulder Planning Software, and InSet Tray System, along with associated instrumentation. The company distributes its products through partners in the United States and aims to reduce operative time and overall healthcare costs while improving post-surgical implant stability. Founded in 2009, the company is based in Holland, Michigan.
GT Medical Technologies
Series D in 2025
GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.
Alleviant Medical
Venture Round in 2025
Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.
Noema Pharma
Series B in 2024
Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.
SynOx Therapeutics
Series B in 2024
SynOx Therapeutics is a biopharmaceutical company focused on developing emactuzumab, a monoclonal antibody targeting CSF-1R, for treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Incorporated in 2019, the company is based in Dublin, Ireland.
Purespring Therapeutics
Series B in 2024
Purespring Therapeutics specializes in developing gene therapies targeting kidney diseases, focusing on podocytes, specialized kidney cells. It is one of the first globally to use AAV gene therapy specifically for kidney conditions.
Moximed develops and provides the Atlas System, an implantable joint unloader designed to alleviate pain and preserve mobility in patients with medial compartment knee osteoarthritis. Its outpatient treatment option aims to improve quality of life for those not responsive to other therapies or candidates for knee replacement.
Draupnir Bio
Seed Round in 2024
Draupnir Bio is focused on developing innovative cholesterol-lowering medications that aim to prevent heart blood clots more effectively than existing treatments. The company leverages a platform technology that explores the glycome to create novel therapeutics through advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. Draupnir Bio specializes in synthesizing, screening, and selecting potent heparan sulfate glycomimetic drug candidates that address cardiovascular, inflammatory, and infectious diseases. Additionally, the company is working on protein degraders that target extracellular disease proteins, which could potentially address a wide range of unmet therapeutic needs across various medical conditions, providing more convenient treatment options compared to traditional injectable therapies.
Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.
Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.
Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.
Argá Medtech
Series B in 2024
Argá Medtech develops a proprietary coherent sine-burst electroporation system designed for treating cardiac arrhythmias. Its technology offers increased power and depth, making it suitable for treating ventricular tachycardia (VT). The system's ease of titration and innovative catheter design eliminate the need for exchanges, providing enhanced flexibility and efficiency in clinical settings.
Mainstay Medical
Private Equity Round in 2024
Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.
Nalu Medical
Series E in 2024
Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.
Koscher & Würtz
Acquisition in 2023
Koscher & Würtz manufactures reusable and disposable surgical instruments for global medical technology companies. The firm focuses on precision hand instruments, modern workstations, and advanced machinery, helping the industry achieve better surgical outcomes and lower costs.
Tagworks Pharmaceuticals
Series A in 2023
Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.
Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.
GT Medical Technologies
Series C in 2023
GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.
FIRE1
Venture Round in 2023
FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.
Noema Pharma
Series B in 2023
Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.
Shoulder Innovations
Series D in 2023
Shoulder Innovations designs and manufactures medical devices for shoulder replacement surgery, focusing on inset glenoid fixation technology to provide a stable glenoid platform and reliable fixation. Its product portfolio includes InSet Total Shoulder Arthroplasty, InSet Reverse Shoulder Arthroplasty, ProVoyance Shoulder Planning Software, and InSet Tray System, along with associated instrumentation. The company distributes its products through partners in the United States and aims to reduce operative time and overall healthcare costs while improving post-surgical implant stability. Founded in 2009, the company is based in Holland, Michigan.
Volta Medical
Series B in 2023
Founded in 2016 and based in Marseille, France, Volta Medical develops artificial intelligence software for interventional cardiology. Its flagship product, AIFib, assists cardiologists in treating atrial fibrillation by analyzing electrograms and guiding cardiac ablation procedures.
Moximed develops and provides the Atlas System, an implantable joint unloader designed to alleviate pain and preserve mobility in patients with medial compartment knee osteoarthritis. Its outpatient treatment option aims to improve quality of life for those not responsive to other therapies or candidates for knee replacement.
Chr. Diener
Acquisition in 2022
Chr. Diener is a contract manufacturer of customer-specific precision surgical instruments.
Ablative Solutions
Series D in 2022
Founded in 2011 and headquartered in San Jose, California with an additional office in Kalamazoo, Michigan, Ablative Solutions is a medical device company specializing in the development of catheters for treating hypertension. Its flagship product, the Peregrine System, enables minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels.
Nalu Medical
Venture Round in 2022
Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.
Splice Bio
Series A in 2022
Splice Bio is a biotechnology company based in Barcelona, Spain, that specializes in developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012, the company focuses on addressing the needs of patients suffering from incurable genetic diseases. Splice Bio's technology, originally developed in the Muir Lab at Princeton University, enhances the capabilities of traditional adeno-associated viruses (AAVs) by allowing for larger gene cargo delivery and targeting a broader range of tissues. This advancement aims to overcome existing limitations in gene therapy, making it a promising solution for treating complex genetic disorders. The company was formerly known as Proteodesign, S.L. before rebranding to Splice Bio in September 2020.
EUROPIN
Acquisition in 2022
EUROPIN is a manufacturer specializing in medical needles, including pen cannulas, lancet needles, and specialized medical needles. The company primarily focuses on the development of injection systems for self-medication, particularly in the areas of diabetes management and hormone therapies. EUROPIN's products are designed to meet precise specifications concerning application, dimensions, bevel, and design, ensuring they align with the needs of the medical and pharmaceutical industries globally. By providing high-quality and innovative needle solutions, EUROPIN supports patients and healthcare professionals in the effective administration of treatments.
Big Health
Series C in 2022
Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.
ProVerum Medical
Series A in 2022
ProVerum Medical is a medtech company that develops minimally invasive devices to treat benign prostatic hyperplasia. Its technology enables safe and effective BPH treatment in a doctor's office or operating room in a less invasive, more patient-friendly manner than traditional approaches. The flexible delivery system uses 3-D geometry to engage prostate anatomy, delivering radial force to the prostatic lobes without cutting, piercing, or heating tissue, with precise deployment under direct visualization. The design is reversible for removal at any time and atraumatic, reducing bleeding and catheterization, and it offers a universal fit to accommodate diverse anatomies, enabling clinicians to treat urinary obstruction caused by prostate enlargement effectively.
Calypso Biotech
Series A in 2021
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in the discovery and development of monoclonal antibodies aimed at treating immune pathologies and addressing significant unmet medical needs. Calypso Biotech focuses on innovative therapies for autoimmune diseases, particularly those affecting patients with severe gastrointestinal conditions such as gastric and pancreatic cancer. The company operates as a semi-virtual organization, leveraging a highly experienced management team with extensive expertise in drug development and a robust scientific network to enhance value for its investors through a portfolio of proprietary antibody candidates.
Spire Health
Venture Round in 2021
Spire Health, established in 2013 and headquartered in San Francisco, specializes in developing health-tracking devices and remote patient monitoring solutions. The company's core product is a wearable device that senses physical movement, position, and breathing patterns, providing insights into daily activities and mental state through a mobile application. Spire Health focuses on chronic respiratory disease management, offering solutions for conditions such as COPD, congestive heart failure, asthma, and sleep disorders. Their mission is to empower patients and physicians with useful, actionable data by harnessing the power of algorithms and sensors, thereby improving health outcomes.
KLIFO offers comprehensive consulting services for pharmaceutical and biotechnology companies. They provide multidisciplinary expertise across clinical research, trial supply management, regulatory affairs, pharmacovigilance, and product development for drugs, biologics, and medical devices.
Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.
Acti-Med
Acquisition in 2021
Acti-Med specializes in the high-quality manufacturing of medical technology components. Its core competency lies in developing and producing cannulas and cannula systems for both medical technology and pharmaceutical industries.
LUMICKS develops innovative technologies for studying biology and cancer at single-molecule and single-cell levels. Its products include C-Trap Optical Tweezers, Fluorescence Microscopy, and z-Movi Cell Avidity Analyzer, enabling real-time analysis of complex biological processes and interactions.
Amphista Therapeutics
Series B in 2021
Founded in 2017, Amphista Therapeutics is a biopharmaceutical company based in Motherwell, UK. It specializes in developing first-in-class cancer therapeutics using targeted protein degradation technology to selectively remove disease-causing proteins.
Volta Medical
Series A in 2021
Founded in 2016 and based in Marseille, France, Volta Medical develops artificial intelligence software for interventional cardiology. Its flagship product, AIFib, assists cardiologists in treating atrial fibrillation by analyzing electrograms and guiding cardiac ablation procedures.
Noema Pharma
Series A in 2020
Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.
Lava Therapeutics
Series C in 2020
Founded in 2016 and headquartered in Utrecht, the Netherlands, Lava Therapeutics is a biotechnology company specializing in the development of proprietary Vγ9Vδ2 T-cell engagers for immune oncology. Its platform focuses on creating bispecific antibodies to engage gamma-delta T cells for treating hematological and solid cancers.
Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.
Eargo, Inc. is a consumer-focused medical device company specializing in the design and sale of hearing aids for individuals with hearing loss in the United States. Founded in 2010 and headquartered in San Jose, California, Eargo offers innovative, rechargeable hearing aids that can be controlled via smartphone, enhancing user convenience. The company provides online hearing screenings and virtual support, eliminating the need for in-person consultations. By adopting a direct-to-consumer model, Eargo aims to make hearing aids more accessible and reduce the social stigma often associated with them. Its user-centric approach addresses the common challenges of traditional hearing aid adoption, including cost and accessibility, thereby improving the quality of life for those with hearing difficulties.
Withings is a developer of digital health and wellness smart devices aimed at empowering individuals to make informed health decisions. The company offers a diverse array of products, including smart scales that help users achieve fitness and weight goals, stylish activity trackers and hybrid smartwatches, and an advanced sleep-tracking mat. Additionally, Withings produces medically accurate devices for monitoring blood pressure and temperature, enabling users to track their health progress effectively. These devices facilitate data sharing with healthcare professionals, enhancing the overall management of personal health.
CVRx
Venture Round in 2020
CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.
Big Health
Series B in 2020
Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.
AM Pharma
Venture Round in 2020
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
Draupnir Bio
Seed Round in 2019
Draupnir Bio is focused on developing innovative cholesterol-lowering medications that aim to prevent heart blood clots more effectively than existing treatments. The company leverages a platform technology that explores the glycome to create novel therapeutics through advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. Draupnir Bio specializes in synthesizing, screening, and selecting potent heparan sulfate glycomimetic drug candidates that address cardiovascular, inflammatory, and infectious diseases. Additionally, the company is working on protein degraders that target extracellular disease proteins, which could potentially address a wide range of unmet therapeutic needs across various medical conditions, providing more convenient treatment options compared to traditional injectable therapies.
AM Pharma
Series F in 2019
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
SANIFIT is a biotechnology company developing treatments for calcification disorders, including progressive vascular calcification and cardiovascular diseases linked to calcification in patients with end-stage renal disease on hemodialysis. It operates as a clinical-stage biopharmaceutical company focused on therapies to prevent or treat calcium-related pathologies that contribute to heart disease in dialysis patients.
CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.
Vesper Medical
Venture Round in 2019
Vesper Medical, Inc. is a medical device company based in Wayne, Pennsylvania, founded in 2016. The company specializes in the development of minimally invasive peripheral vascular products aimed at treating patients with deep venous disease. Its primary offering is the Vesper DUO Venous Stent System, designed specifically for venous stenting. This system features a unique combination of strength and flexibility to address the complex anatomical challenges encountered in the iliac and femoral veins. Vesper Medical is dedicated to creating safe, effective, and user-friendly products that enhance patient care and support healthcare providers in improving patient outcomes in venous treatment.
Eetgemak
Acquisition in 2019
Eetgemak BV, established in 2006 and located in Katwijk, the Netherlands, specializes in the production of ready-made meals tailored for various sectors, including healthcare and education. The company offers a diverse range of chilled and frozen meal options, including regular, biological, vegetarian, and multicultural dishes, as well as specialized dietary meals. Its clientele consists of hospitals, nursing homes, residential care centers, home care organizations, schools, daycare centers, and catering establishments. Eetgemak’s products are designed to support the nutritional needs and well-being of patients and residents, ensuring that meals are both convenient and health-conscious.
Calypso Biotech
Series A in 2019
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in the discovery and development of monoclonal antibodies aimed at treating immune pathologies and addressing significant unmet medical needs. Calypso Biotech focuses on innovative therapies for autoimmune diseases, particularly those affecting patients with severe gastrointestinal conditions such as gastric and pancreatic cancer. The company operates as a semi-virtual organization, leveraging a highly experienced management team with extensive expertise in drug development and a robust scientific network to enhance value for its investors through a portfolio of proprietary antibody candidates.
Ablative Solutions
Series D in 2019
Founded in 2011 and headquartered in San Jose, California with an additional office in Kalamazoo, Michigan, Ablative Solutions is a medical device company specializing in the development of catheters for treating hypertension. Its flagship product, the Peregrine System, enables minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels.
Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.
Vapotherm
Series D in 2018
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.
Lava Therapeutics
Series A in 2018
Founded in 2016 and headquartered in Utrecht, the Netherlands, Lava Therapeutics is a biotechnology company specializing in the development of proprietary Vγ9Vδ2 T-cell engagers for immune oncology. Its platform focuses on creating bispecific antibodies to engage gamma-delta T cells for treating hematological and solid cancers.
Axonics Modulation Technologies
Series C in 2018
Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.
Inari Medical
Series C in 2018
Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.
Performation
Acquisition in 2018
Performation Healthcare Intelligence is a prominent provider of healthcare-specific business intelligence solutions in the Netherlands. The company specializes in software, data analysis, and advisory services aimed at helping healthcare organizations monitor costs, processes, and quality. With a dedicated team of over a hundred consultants and business intelligence experts, Performation enables its clients to make informed decisions that enhance the delivery of effective and high-quality care. By addressing healthcare-wide information challenges and integrating data into actionable insights, the company supports its clients in optimizing their operations and improving patient outcomes.
FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.
Axonics Modulation Technologies
Series C in 2017
Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.
Vapotherm
Series D in 2017
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.
Moximed develops and provides the Atlas System, an implantable joint unloader designed to alleviate pain and preserve mobility in patients with medial compartment knee osteoarthritis. Its outpatient treatment option aims to improve quality of life for those not responsive to other therapies or candidates for knee replacement.
Breath Therapeutics
Series A in 2017
Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, specializes in developing innovative drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016 and operating as a subsidiary of Zambon S.p.A., the company focuses on creating novel formulations of existing drugs combined with advanced inhalation technologies. Their drug-device combinations are designed to deliver high concentrations of therapeutics directly to the lungs, enhancing efficacy while minimizing systemic exposure. This approach targets rare respiratory diseases with significant unmet medical needs, positioning Breath Therapeutics at the forefront of inhalation therapy advancements.
LUMICKS develops innovative technologies for studying biology and cancer at single-molecule and single-cell levels. Its products include C-Trap Optical Tweezers, Fluorescence Microscopy, and z-Movi Cell Avidity Analyzer, enabling real-time analysis of complex biological processes and interactions.
Nyxoah focuses on developing and commercializing solutions to treat sleep-disordered breathing conditions. Its primary product is the Genio system, a CE-Mark validated bilateral neuro-stimulation therapy for moderate to severe obstructive sleep apnea.
NightBalance
Series B in 2016
NightBalance B.V., established in 2009, is a medical technology company that develops innovative solutions to improve sleep quality. Originating from research at Delft University of Technology, the company specializes in creating a smart therapy device designed to treat positional obstructive sleep apnea. This medical device, the Sleep Position Trainer, measures a patient's sleep behavior and prevents apnea episodes, allowing users to achieve more comfortable and restful sleep.
STAT-Diagnostica is a company dedicated to the development of near-patient testing products aimed at enhancing healthcare delivery. It specializes in creating point-of-care diagnostic devices designed for rapid turnaround applications and critical care environments. The company's flagship product, DiagCORE, is a portable multi-analyte instrument that supports both molecular and immunoassay testing across various clinical settings. By integrating multiple testing techniques into a single device, STAT-Diagnostica enables healthcare professionals to streamline patient care and improve diagnostic efficiency.
NIZO
Private Equity Round in 2016
NIZO food research BV is an independent contract research organization based in Ede, the Netherlands, with additional offices in the United States, France, and Japan. Founded in 1948, NIZO specializes in providing research and innovation services to the dairy, food and beverage, ingredients, and biotech industries. The company focuses on developing new flavors and textures, utilizing advanced technologies to enhance food products while addressing sustainability, cost-effectiveness, and speed to market. NIZO's offerings include analysis, contract research, production services, webinars, white papers, training programs, and pre-competitive research. The company also operates a food-grade processing plant to bring innovative food technologies to life.
Moximed develops and provides the Atlas System, an implantable joint unloader designed to alleviate pain and preserve mobility in patients with medial compartment knee osteoarthritis. Its outpatient treatment option aims to improve quality of life for those not responsive to other therapies or candidates for knee replacement.
BionX™ Medical Technologies
Series E in 2015
BionX Medical Technologies specializes in manufacturing advanced prosthetic devices aimed at enhancing the mobility and quality of life for individuals with amputations. The company's flagship product, the BiOM Ankle, features powered propulsion that allows for more natural movement by simulating human-like gait mechanics. This innovative prosthesis utilizes sophisticated microprocessors and environmental sensors to continuously assess and adjust its performance, providing users with the ability to navigate various terrains, including slopes and stairs, with reduced energy expenditure. BionX Medical Technologies serves its clientele through a network of prosthetists and healthcare providers, both in the United States and internationally. Founded in 2007 and headquartered in Bedford, Massachusetts, the company transitioned from its former name, iWalk, Inc., in 2015 and is currently a subsidiary of Otto Bock HealthCare GmbH.
SANIFIT is a biotechnology company developing treatments for calcification disorders, including progressive vascular calcification and cardiovascular diseases linked to calcification in patients with end-stage renal disease on hemodialysis. It operates as a clinical-stage biopharmaceutical company focused on therapies to prevent or treat calcium-related pathologies that contribute to heart disease in dialysis patients.
Vapotherm
Series C in 2015
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.
Zetacom
Acquisition in 2015
Zetacom is a systems integrator specializing in communication, network, and security solutions tailored for the corporate and healthcare sectors. The company provides comprehensive services to healthcare institutions, semi-government bodies, corporations, and small to medium enterprises (SMEs). Zetacom's offerings include the installation and maintenance of network infrastructures, telecommunication systems, and speech and data integration solutions. Additionally, the company supports DSL applications, contact centers, voice-over IP systems, and network security services. By focusing on reliable, cost-effective, and flexible solutions, Zetacom aims to enhance the communication capabilities of its clients across various industries.
Zetacom
Private Equity Round in 2015
Zetacom is a systems integrator specializing in communication, network, and security solutions tailored for the corporate and healthcare sectors. The company provides comprehensive services to healthcare institutions, semi-government bodies, corporations, and small to medium enterprises (SMEs). Zetacom's offerings include the installation and maintenance of network infrastructures, telecommunication systems, and speech and data integration solutions. Additionally, the company supports DSL applications, contact centers, voice-over IP systems, and network security services. By focusing on reliable, cost-effective, and flexible solutions, Zetacom aims to enhance the communication capabilities of its clients across various industries.
Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.
Moximed develops and provides the Atlas System, an implantable joint unloader designed to alleviate pain and preserve mobility in patients with medial compartment knee osteoarthritis. Its outpatient treatment option aims to improve quality of life for those not responsive to other therapies or candidates for knee replacement.
Novicare
Private Equity Round in 2015
Novicare is a healthcare provider that specializes in delivering high-quality treatment services to nursing homes and individuals requiring home care. The company focuses on complex and chronic conditions, utilizing multidisciplinary self-managed teams to enhance the quality of (para) medical care. Novicare employs a diverse range of healthcare professionals, including geriatricians, psychologists, physiotherapists, occupational therapists, speech therapists, and dieticians, to address the varied needs of its clients. In addition to providing direct care, Novicare offers educational programs, interim management, and consultancy services to nursing homes, ensuring transparency and a strong commitment to patient involvement. Under its brand VitaalThuis, Novicare also extends its services to individuals receiving care at home, linking effective treatment with the actual needs of patients, particularly the elderly and those with intellectual disabilities.
AM Pharma
Series E in 2014
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
Definiens
Venture Round in 2014
Definiens is a provider of image analysis and data mining solutions specifically designed for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. The company's software delivers detailed insights from whole tissue slides, cell-based assays, and full body scans, enabling the integration of this information with data from various sources. By automating analysis workflows, Definiens enhances the capabilities of pharmaceutical and biotechnology companies, research institutions, clinical service organizations, and pathologists, facilitating informed decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, with additional offices in the United States, Definiens aims to advance research, contribute to the development of personalized medicine, and improve patient outcomes.
Vapotherm
Series B in 2014
Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.
Viroclinics Biosciences
Acquisition in 2014
Viroclinics Biosciences is a prominent contract research and clinical laboratory service provider specializing in virology. The company focuses on diagnostic and preclinical studies, as well as drug development aimed at preventing and treating viral infections, particularly respiratory viruses like influenza. Viroclinics offers an extensive range of virology services that support both new drug development programs and post-marketing surveillance of existing drugs and vaccines. Their capabilities include traditional virology assays and advanced deep sequencing protocols applicable to a wide variety of viruses. Operating BSL2 and BSL3 laboratories, Viroclinics conducts analyses in compliance with international ISO 15189 accreditation standards. The company collaborates closely with the Erasmus MC Viroscience lab, enhancing its expertise in developing antivirals and vaccines while serving the biopharmaceutical community with tailored models for preclinical drug testing and expert guidance.
Sapiens Steering Brain Stimulation
Series C in 2013
Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.
Acacia Pharma
Series B in 2013
Acacia Pharma is a pharmaceutical company dedicated to discovering and developing supportive care drugs. Its primary focus is on cancer supportive care, with products including BAREMSIS for post-operative nausea and vomiting, APD403 for chemotherapy-induced nausea and vomiting, and BYFAVO for sedation during invasive medical procedures. The company serves anesthesiologists and oncologists, aiming to improve the care of patients undergoing serious medical treatments.
Pharmaline
Private Equity Round in 2012
Pharmaline is an innovative semi-industrial compounding pharmacy located in Oldenzaal, Netherlands. Established in 2009 with 30 employees, the company has grown to over 140 staff members, all operating under the latest Good Manufacturing Practice (GMP) guidelines. Pharmaline provides a comprehensive range of pharmaceutical solutions, serving approximately 700 pharmacists across the Netherlands. The company focuses on standardization and rationalization to enhance the quality of care while reducing healthcare costs. Its offerings include both stock preparations and ad hoc preparations tailored to patient needs, encompassing creams, ointments, tablets, capsules, drops, liquids, suspensions, and injectables. Pharmaline aims to be a one-stop solution for pharmacy preparations, ensuring that pharmacists have easy access to necessary products. The company employs experienced pharmacists who provide expert advice on various aspects of pharmacotherapy, production engineering, application engineering, and legislation, all supported by modern equipment.
Definiens
Venture Round in 2012
Definiens is a provider of image analysis and data mining solutions specifically designed for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. The company's software delivers detailed insights from whole tissue slides, cell-based assays, and full body scans, enabling the integration of this information with data from various sources. By automating analysis workflows, Definiens enhances the capabilities of pharmaceutical and biotechnology companies, research institutions, clinical service organizations, and pathologists, facilitating informed decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, with additional offices in the United States, Definiens aims to advance research, contribute to the development of personalized medicine, and improve patient outcomes.
BionX™ Medical Technologies
Series D in 2012
BionX Medical Technologies specializes in manufacturing advanced prosthetic devices aimed at enhancing the mobility and quality of life for individuals with amputations. The company's flagship product, the BiOM Ankle, features powered propulsion that allows for more natural movement by simulating human-like gait mechanics. This innovative prosthesis utilizes sophisticated microprocessors and environmental sensors to continuously assess and adjust its performance, providing users with the ability to navigate various terrains, including slopes and stairs, with reduced energy expenditure. BionX Medical Technologies serves its clientele through a network of prosthetists and healthcare providers, both in the United States and internationally. Founded in 2007 and headquartered in Bedford, Massachusetts, the company transitioned from its former name, iWalk, Inc., in 2015 and is currently a subsidiary of Otto Bock HealthCare GmbH.
Santaris Pharma
Venture Round in 2012
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.
Agendia
Private Equity Round in 2012
Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide decisions on chemotherapy, hormonal therapy, or alternative treatments, thereby improving patient outcomes and reducing healthcare costs.
Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled respiratory medicines for conditions such as asthma and chronic obstructive pulmonary disease. Established in 2006, Prosonix specializes in generic mono and combination therapies that utilize inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. The company employs proprietary ultrasonic particle engineering technologies to create and optimize drug formulations, enhancing the delivery and effectiveness of its inhaled medications. Prosonix is recognized for its innovative approach to developing new methods for transforming molecules into particles suitable for inhalation, allowing for tailored therapeutic solutions. As of June 2015, Prosonix operates as a subsidiary of Circassia Limited.
Moximed
Venture Round in 2012
Moximed develops and provides the Atlas System, an implantable joint unloader designed to alleviate pain and preserve mobility in patients with medial compartment knee osteoarthritis. Its outpatient treatment option aims to improve quality of life for those not responsive to other therapies or candidates for knee replacement.
Inova Labs
Series B in 2011
Inova Labs, Inc. is a medical device development and manufacturing company based in Austin, Texas. Established in 2002, it specializes in creating innovative products for direct patient care, particularly focusing on oxygen delivery solutions for individuals with respiratory conditions. The company’s flagship products include the LifeChoice stationary and portable oxygen concentrators, which utilize a pulse mode system to provide varying levels of supplemental oxygen. Inova Labs also offers a range of accessories, such as carrying cases, external batteries, and power adapters. These products are distributed through authorized providers, primarily via their online platforms, ensuring accessibility for patients in need of oxygen therapy.
Fysius Rugexperts
Private Equity Round in 2011
Fysius Rugexperts is a leading chain of clinics in the Netherlands that specializes in treating lower-back and related pains. Utilizing the latest scientific insights, Fysius employs advanced treatment methods and aids, including the OriGENE device, to address chronic back and spinal pain. With a strong focus on patient care, the clinic treats over 10,000 patients annually, making it the largest and most specialized facility for back pain in the country. Fysius aims to help individuals maintain their health and fitness by effectively addressing spine-related issues.
ProFibrix
Series B in 2011
ProFibrix B.V. is a biotechnology company focused on developing and marketing innovative products for the hemostasis and regenerative medicine sectors. Founded in 2004, the company specializes in Fibrocaps, a dry powder topical hemostat and tissue sealant designed to effectively control acute and severe bleeding during surgical procedures or due to traumatic injuries. Fibrocaps is formulated from a blend of fibrinogen and thrombin, two key proteins vital for blood clotting and tissue repair. Additionally, ProFibrix offers a sterilized single-use delivery device that facilitates the application of Fibrocaps to targeted areas, minimizing the need to manipulate the wound in a surgical setting. The company's products leverage human fibrinogen, a natural blood protein, to enhance hemostatic efficacy and promote healing.
VerzuimVitaal
Private Equity Round in 2011
VerzuimVitaal B.V. is a Dutch company that specializes in providing occupational health services aimed at managing employee absenteeism. Founded in 2011 and located in Woerden, the Netherlands, the company focuses on enhancing the vitality of organizations and their employees to reduce absenteeism costs. In addition to promoting employee wellness, VerzuimVitaal oversees the management of sick leave and the reintegration process for employees returning to work.
Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled respiratory medicines for conditions such as asthma and chronic obstructive pulmonary disease. Established in 2006, Prosonix specializes in generic mono and combination therapies that utilize inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. The company employs proprietary ultrasonic particle engineering technologies to create and optimize drug formulations, enhancing the delivery and effectiveness of its inhaled medications. Prosonix is recognized for its innovative approach to developing new methods for transforming molecules into particles suitable for inhalation, allowing for tailored therapeutic solutions. As of June 2015, Prosonix operates as a subsidiary of Circassia Limited.
Acacia Pharma
Series A in 2011
Acacia Pharma is a pharmaceutical company dedicated to discovering and developing supportive care drugs. Its primary focus is on cancer supportive care, with products including BAREMSIS for post-operative nausea and vomiting, APD403 for chemotherapy-induced nausea and vomiting, and BYFAVO for sedation during invasive medical procedures. The company serves anesthesiologists and oncologists, aiming to improve the care of patients undergoing serious medical treatments.